A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The aim of this pilot study is to determine the safety and efficacy of risperidone for the
treatment of anorexia nervosa.
Hypothesis 1: Subjects on risperidone will show a more significant decrease in body image
distortion and Eating Disorder Inventory -2 scores than subjects on placebo.
Hypothesis 2: Subjects on risperidone will reach and maintain at or above 90% Ideal body
weight sooner than controls.
Phase:
Phase 4
Details
Lead Sponsor:
University of Colorado, Denver
Collaborators:
Janssen Pharmaceuticals National Center for Research Resources (NCRR)